Abstract 4662: Genetic Variations in the Cell-Cycle Pathway and Survival of Patients with Advanced Non-Small Cell Lung Cancer Receiving Platinum-Based Chemotherapy

Jikai Yin,Xifeng Wu,Charles Lu,Joe Chang,Michelle Hildebrandt,David Stewart,Margaret R. Spitz,Jian Gu
DOI: https://doi.org/10.1158/1538-7445.am10-4662
IF: 11.2
2010-01-01
Cancer Research
Abstract:Abstract Background: Platinum-based chemotherapy is the main choice of treatment for patients with advanced Non-small cell lung cancer (NSCLC). Platinum agents target DNA preferentially for cytotoxicity, which will lead to DNA damage and cell-cycle arrest. We hypothesize that genetic variations in cell cycle pathway may modulate response to platinum-based chemotherapy. In this study, we utilized a comprehensive pathway-based approach to identify genetic variations in the cell-cycle pathway as predictors of overall survival in NSCLC patients treated with platinum-based chemotherapy. Material and Methods: We genotyped 633 polymorphisms from 105 cell cycle-related genes in 598 advanced NSCLC cases who received first-line platinum-based chemotherapy. All genotypes were analyzed for association with overall survival and evaluated for potential cumulative and gene-gene interactions that further modulated overall survival. Multiple statistic analyses were applied, including individual SNP analysis, cumulative genotype analysis, haplotype analysis, survival tree analysis and Kaplan-Meier survival analysis. Results: 65 SNPs from 40 cell-cycle genes were identified that were significantly associated with NSCLC overall survival (p<0.05) individually. We found that increasing numbers of potential high-risk alleles in any cell-cycle checkpoint would lead to increased risk of death. Compared with other checkpoints, G1/S checkpoint showed more significant associations with patients’ survival. For the combined analysis of unfavorable genotypes in G1/S checkpoint, compared with the referent group (≤20 unfavorable genotypes), the HRs for patients carrying 21-23 and 24-32 unfavorable genotypes were 1.94(95%CI 1.47-2.56) and 3.00(95%CI 2.33-3.85), respectively (p for trend < 0.0001), and also a significant reduction of median survival time from 24.05 to 9.18 months (log-rank p < 0.0001). Heplotype analysis revealed that a TP73 haplotype (GTGTTA) was significantly associated with increased risk of death (p=0.00026). Survival tree analysis of overall cell-cycle pathway indicated G1/S checkpoint genes categorized patients into subgroups with different survival pattern. Conclusions: These results suggest that G1 and G1/S checkpoint genetic variations affect survival of advanced NSCLC patients treated with platinum-based chemotherapy and that there are gene-dosage effect and gene-gene interactions in modulating clinical outcomes. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 4662.
What problem does this paper attempt to address?